Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer (Q42082392)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

0 references

samarium (153sm) lexidronam

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

author name string

Shi-Ming Tu

1

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Paul Mathew

2

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Franklin C Wong

3

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Donnah Jones

4

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Marcella M Johnson

5

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Christopher J Logothetis

6

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

language of work or name

0 references

publication date

4 May 2009

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

27

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

20

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

3319-3324

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371137

30 May 2018

Current trials using bone-targeting agents in prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371137

30 May 2018

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371137

30 May 2018

Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371137

30 May 2018

Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371137

30 May 2018

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371137

30 May 2018

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371137

30 May 2018

Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371137

30 May 2018

Mechanisms of Osteoblastic Metastases: Role of Endothelin-1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371137

30 May 2018

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371137

30 May 2018

Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371137

30 May 2018

Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371137

30 May 2018

Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371137

30 May 2018

Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371137

30 May 2018

Spread of prostatic cancer to bone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371137

30 May 2018

A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371137

30 May 2018

Dose-finding study of weekly docetaxel plus estramustine in patients with hormone-refractory metastatic prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371137

17 August 2018

Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371137

17 August 2018

Strontium-89 therapy: measurement of absorbed dose to skeletal metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/19414670

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19414670

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduced incidence of bone metastases in irradiated areas after external radiation therapy of prostatic carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19414670

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2008.20.5393

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42082392&oldid=1966885126"